Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial

Abstract Patients with residual nasopharyngeal carcinoma after receiving definitive treatment have poor prognoses. Although immune checkpoint therapies have achieved breakthroughs for treating recurrent and metastatic nasopharyngeal carcinoma, none of these strategies have been assessed for treating...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Xun Cao, Hao-Yang Huang, Chi-Xiong Liang, Zhuo-Chen Lin, Jia-Yu Zhou, Xi Chen, Ying-Ying Huang, Ze-Jiang Zhan, Liang-Ru Ke, Lu-Jun Han, Wei-Xiong Xia, Lin-Quan Tang, Shan-Shan Guo, Hu Liang, Xiang Guo, Xing Lv
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Nature Portfolio 2024-01-01
Cyfres:	Nature Communications
Mynediad Ar-lein:	https://doi.org/10.1038/s41467-024-45276-1
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!